# A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection

> **NCT05467553** · PHASE2 · UNKNOWN · sponsor: **National Taiwan University Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Hepatitis D

## Interventions

- **DRUG:** Ursodeoxycholic acid
- **DRUG:** Ropeginterferon alfa-2b
- **DRUG:** Tenofovir Alafenamide

## Key facts

- **NCT ID:** NCT05467553
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-24
- **Primary completion:** 2025-02-28
- **Final completion:** 2025-08-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-12-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05467553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05467553, "A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05467553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*